You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Harvard Business School
Dow
Merck

Last Updated: April 10, 2020

DrugPatentWatch Database Preview

Litigation Details for Endo Pharmaceuticals Inc. v. Impax Laboratories Inc. (D. Del. 2007)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Endo Pharmaceuticals Inc. v. Impax Laboratories Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-11-15
Court District Court, D. Delaware Date Terminated 2009-02-24
Cause 35:271 Patent Infringement Assigned To Katharine S. Hayden
Jury Demand None Referred To
Parties ENDO PHARMACEUTICALS INC.; IMPAX LABORATORIES INC.; PENWEST PHARMACEUTICALS CO.
Patents 4,569,937; 4,839,177; 4,851,229; 4,861,598; 4,892,741; 5,128,143; 5,543,434; 5,662,933; 5,948,438; 5,958,452; 5,958,456; 5,965,161; 6,294,195; 6,309,663; 7,276,250
Attorneys Jack B. Blumenfeld; Julia Heaney; Mary Matterer
Firms Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Endo Pharmaceuticals Inc. v. Impax Laboratories Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Endo Pharmaceuticals Inc. v. Impax Laboratories Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-11-15 1 Complaint Sunshine et al. 6’555,127 132 4;2003 Ste{ner 4,569,937 A "‘ 2/1986 Baker et al. 514/282 61527!635…United States Patent Nos. 5,662,933 (“the ‘933 patent”) and 5,958,456 (“the ‘456 patent”). This action…United States Patent [19] Baichwal et al. [11] Patent Number: 5,958,456 -[45] Date of Patent: *Sep. 28,…1997, the U.S. Patent and Trademark Office (“PTO”) duly and legally issued the ‘933 patent, entitled “Controlled…and legally issued United States Patent No. 7,276,250 (“the ‘250 patent”), entitled “Sustained Release External link to document
2007-12-20 13 Motion to Strike is the reference to the unasserted U.S. Patent No, 7,276,250, should be stricken from Paragraph 27. …that the allegations Were related to the remaining patent inh‘ingement causes of action in the Complaint … Paragraph IV Notices from a complaint alleging patent infringement, Biovail Labs. v. Torpharm, Inc., … 24 February 2009 1:07-cv-00731 830 Patent None District Court, D. Delaware External link to document
2008-01-14 21 Response to Motion , the U.S. Patent & Trademark Office (“PTO”) issued United States Patent No. 7,276,250 (“the ‘250 …Paragraph IV Patent Certification Notice U.S. Patent Nos. 5,662,933; 5,958,456; and 7,276,250 IMPAX Laboratories…Certitications with respect to U.S. Patent Nos. 5,662,933; 5,958,456; and 7,276,250. Detailed statements ofthe …of the Factual and Legal Bases That U.S. Patent No. 7,276,250 is lnvalid, Unenforceable and/or Not Infr…regarding two additional patents _ United States Patent Nos. 5,662,933 (“the ‘933 patent”) and 5,958,456 (“the External link to document
2008-01-25 27 Reply Brief ANDA patent litigation process With respect to United States Patent No. 7,276,250 (“the ‘250 patent”), …submitted information regarding U.S. Patent No. 7,276,250 (“’250 patent”)_which Endo has not alleged Impax…its product does not infringe US Patent No. 7,276,250, or that the patent is invalid or unenforceable Following… 5,958,456; 7,276,250, collectively the ‘_‘Listed Patents”). Therefore, Impax wishes to provide Endo and…certification notice refers to Penwest's U.S. Patent Nos. 7,276,250, 5,958,456 and 5,662,933, which cover the External link to document
2008-09-05 39 Motion to Transfer Case Pat. No. 4,839,177, hereby incorporated by reference herein in its entirety. ln that patent, the support… Pat. No. 4,839,177, hereby incorporated by reference herein in its entirety. In that patent, the support…infringing U.S. Patent No. 5,662,933 (the “’933 patent”) and U.S. Patent No. 5,958,456 (the “’456 patent”) by submitting…the ’456 patent and/or prior patents in the same patent family. 27. On its face, the ’456 patent was filed…United States Patent No. 5,958,456 (“the ‘456 patent”). This action is based upon the Patent Laws of the External link to document
2007-11-20 6 Motion for Declaratory Judgment ANDA patent litigation process with respect to United States Patent No. 7,276,250 (“the ‘250 patent”), …, United States Patent No. 5,662,933 (“the ‘933 patent”), or United States Patent No. 5,958,456 (“the …the ‘456 patent” ; B. This Court has no subject matter jurisdiction over claims between Plaintiffs and …regarding infringement of the ‘250, ‘933 or ‘456 patents because the Paragraph IV Notices served by linan…did not commence the 45-day period for filing a patent infringement action pursuant to 21 U.S.C. § 355 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Harvard Business School
Johnson and Johnson
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.